Health ❯ Healthcare ❯ Clinical Trials ❯ Phase III Trials

ASCENT-07 Trial

Sacituzumab Govitecan Gains First-Line Ground in TNBC, Falls Short in Early HR+/HER2− Use

SABCS presentations underscore subtype‑specific use requiring careful treatment sequencing.